446 related articles for article (PubMed ID: 10348263)
1. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
Douay L; Hu C; Giarratana MC; Gorin NC
Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773
[TBL] [Abstract][Full Text] [Related]
3. Use of amifostine in bone marrow purging.
Cagnoni PJ; Jones RB; Bearman SI; Ross M; Hami L; Franklin WA; Capizzi R; Schein PS; Shpall EJ
Semin Oncol; 1996 Aug; 23(4 Suppl 8):44-8. PubMed ID: 8783666
[TBL] [Abstract][Full Text] [Related]
4. Protection by amifostine of cyclophosphamide-induced myelosuppression.
Alberts DS
Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
[TBL] [Abstract][Full Text] [Related]
5. Neurologic protection by amifostine.
DiPaola RS; Schuchter L
Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
[TBL] [Abstract][Full Text] [Related]
6. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D
Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203
[TBL] [Abstract][Full Text] [Related]
7. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo expansion of bone marrow from breast cancer patients: reduction in tumor cell content through passive purging.
Lundell BI; Vredenburgh JJ; Tyer C; DeSombre K; Smith AK
Bone Marrow Transplant; 1998 Jul; 22(2):153-9. PubMed ID: 9707023
[TBL] [Abstract][Full Text] [Related]
9. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
Phillips GL
Semin Oncol; 2002 Dec; 29(6 Suppl 19):53-6. PubMed ID: 12577245
[TBL] [Abstract][Full Text] [Related]
10. Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide.
Grdina DJ; Hunter N; Kataoka Y; Murley JS; Milas L
Semin Oncol; 1999 Apr; 26(2 Suppl 7):22-7. PubMed ID: 10348256
[TBL] [Abstract][Full Text] [Related]
11. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
[TBL] [Abstract][Full Text] [Related]
12. Future directions in non-small cell lung cancer.
Schiller JH
Semin Oncol; 1999 Apr; 26(2 Suppl 7):120-4. PubMed ID: 10348270
[TBL] [Abstract][Full Text] [Related]
13. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
14. Amifostine and combined-modality therapeutic approaches.
Mehta MP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):95-101. PubMed ID: 10348267
[TBL] [Abstract][Full Text] [Related]
15. Purging of small cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated merocyanine 540 phototreatment.
Meagher RC; Rothman SA; Paul P; Koberna P; Willmer C; Baucco PA
Cancer Res; 1989 Jul; 49(13):3637-41. PubMed ID: 2543500
[TBL] [Abstract][Full Text] [Related]
16. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
Gidáli J; Fehér I
Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
[TBL] [Abstract][Full Text] [Related]
17. Radioprotective effects of amifostine.
Wasserman T
Semin Oncol; 1999 Apr; 26(2 Suppl 7):89-94. PubMed ID: 10348266
[TBL] [Abstract][Full Text] [Related]
18. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
19. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.
Lopez M; Mary JY; Sainteny F
Exp Hematol; 1993 Feb; 21(2):311-8. PubMed ID: 8425567
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
Jiang R; Bony V; Lopez M
Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
[No Abstract] [Full Text] [Related]
[Next] [New Search]
